YU55998A - Oral or implant pharmaceutical formulation with controlled release - Google Patents

Oral or implant pharmaceutical formulation with controlled release

Info

Publication number
YU55998A
YU55998A YU55998A YU55998A YU55998A YU 55998 A YU55998 A YU 55998A YU 55998 A YU55998 A YU 55998A YU 55998 A YU55998 A YU 55998A YU 55998 A YU55998 A YU 55998A
Authority
YU
Yugoslavia
Prior art keywords
oral
controlled release
pharmaceutical formulation
implant
implant pharmaceutical
Prior art date
Application number
YU55998A
Other languages
English (en)
Serbo-Croatian (sh)
Serbian (sr)
Inventor
C Nay John Leeper
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU55998A publication Critical patent/YU55998A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
YU55998A 1996-06-06 1998-12-04 Oral or implant pharmaceutical formulation with controlled release YU55998A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65946396A 1996-06-06 1996-06-06

Publications (1)

Publication Number Publication Date
YU55998A true YU55998A (en) 1999-11-22

Family

ID=24645503

Family Applications (1)

Application Number Title Priority Date Filing Date
YU55998A YU55998A (en) 1996-06-06 1998-12-04 Oral or implant pharmaceutical formulation with controlled release

Country Status (17)

Country Link
EP (1) EP0914128A1 (cs)
JP (1) JP2000511906A (cs)
KR (1) KR20000016406A (cs)
CN (1) CN1226166A (cs)
AU (1) AU3233197A (cs)
BR (1) BR9709546A (cs)
CA (1) CA2256720A1 (cs)
CZ (1) CZ397698A3 (cs)
EA (1) EA199900006A1 (cs)
HU (1) HUP0003885A2 (cs)
IL (1) IL126966A0 (cs)
NO (1) NO985695L (cs)
PL (1) PL330637A1 (cs)
TR (1) TR199802496T2 (cs)
WO (1) WO1997046241A1 (cs)
YU (1) YU55998A (cs)
ZA (1) ZA974978B (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19815411A1 (de) * 1998-04-06 1999-10-07 Solvay Pharm Gmbh Thermogenese stimulierend wirksame Arzneimittel
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
DK1150680T3 (da) * 1999-02-01 2005-03-07 Solvay Pharm Gmbh Anvendelse af moxonidin til behandling efter hjerteinfarkt
EP1894927B1 (en) * 2006-08-31 2010-11-10 Chemagis Ltd. The use of moxonidine salts for purification of moxonidine
KR100812287B1 (ko) * 2007-01-03 2008-03-13 주식회사 챠콜코리아 내면에 반사층을 갖는 신호등 갓

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
DE3617158C2 (de) * 1986-05-22 1994-10-06 Lohmann Therapie Syst Lts Transdermales Arzneimittel
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
DE3904795C2 (de) * 1989-02-17 2000-10-12 Lilly Pharma Produktion Gmbh & Pharmazeutisches Präparat und dessen Verwendung
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE4423177A1 (de) * 1994-07-01 1996-01-04 Kali Chemie Pharma Gmbh Antihyperglykämisch wirksame Arzneimittel
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal

Also Published As

Publication number Publication date
IL126966A0 (en) 1999-09-22
NO985695L (no) 1999-02-04
CA2256720A1 (en) 1997-12-11
PL330637A1 (en) 1999-05-24
WO1997046241A1 (en) 1997-12-11
CN1226166A (zh) 1999-08-18
HUP0003885A2 (hu) 2001-04-28
NO985695D0 (no) 1998-12-04
AU3233197A (en) 1998-01-05
EP0914128A1 (en) 1999-05-12
CZ397698A3 (cs) 1999-05-12
JP2000511906A (ja) 2000-09-12
BR9709546A (pt) 1999-08-10
EA199900006A1 (ru) 1999-06-24
ZA974978B (en) 1998-12-07
TR199802496T2 (xx) 1999-02-22
KR20000016406A (ko) 2000-03-25

Similar Documents

Publication Publication Date Title
SE9901973L (sv) Implantat för applicering i ben och förfarande och användning vid sådant implantat
DK0671957T3 (da) Fremgangsmåde til behandling af et kirurgisk implanat af metal
TR199802441A3 (tr) Kanda asiri ürik asit bulunmasinin tedavisi ve önlenmesi için yöntem ve terkip.
DE69526937D1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
DK0726765T3 (da) Apparat og fremgangsmåde til fremstilling af faste former med styret frigivelse af den aktive bestanddel
DE69814394D1 (de) Verwendung von levobupivacain
ZA984463B (en) Fused dihydropyrans
ITBO920452A0 (it) "metodo per la realizzazione di protesi da implantologia e dispositivoper l'attuazione di tale metodo".
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
IL122737A0 (en) Salts of amidine derivative and cyclooxygenase inhibitors their preparation and pharmaceutical compositions containing them
FI971622L (fi) Hammasimplanttijärjestelmä ja menetelmä sen valmistamiseksi
DE3852389D1 (de) Rissformungsverhütung in implantierten Prothesen.
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
FI963947A7 (fi) Täydellisesti liuennut luukudos ja menetelmä sen valmistamiseksi
NO985695L (no) Formulering og fremgangsmÕte for Õ behandle kongestiv hjerteinfarkt
ITBO970245A0 (it) Dispositivo e metodo di ancoraggio per l'impianto di stents biforcati.
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
MXPA01008247A (es) Composicion dental formdora de pelicula resistente al acido y metodo de uso de la misma.
EE04951B1 (et) R-(+)-alfa-(2,3-dimetoksfenl)-1-[2-(4-fluorofenl)etl]-4-piperidiinmetanooli kasutamine uneh„irete raviks
ITRM940240A0 (it) Impianto endosseo e presa di finitura per moncone protesico.
KR900007413A (ko) 에이즈 발병방지, 치료제 및 그 치료용 조성물
UA18990A (uk) Зубhий імплаhтат
IT1279984B1 (it) Armatura per la realizzazione di implantoprotesi dentarie, rimovibili, in particolare provvisorie